National and Kapodistrian University of Athens
Η προσβολή των οστών σε αιματολογικά νοσήματα: παθογένεια – αντιμετώπιση
Abstract
dc:descriptionMultiple Myeloma (MM) is a relatively frequent hematological neoplasm characterized by bone marrow (BM) infiltration by plasma cells secreting a monoclonal component in the serum or urine. Disease symptomatology includes a wide range of manifestations among whose skeletal ones are the most frequent. Aim: To investigate aspects of the underlying biology in terms of microenvironmental cytokines involved in the Myeloma Bone Disease (MBD) such as RANKL, IL-6 / s-IL-6, Dkk-1, s-Syndecan-1, b-FGF, TGF-b1 and VEGF and to correlate them with skeletal manifestations and other disease factors. Moreover, we aimed at presenting the treatment options concerning bone disease. Patients and Methods: We studied 177 patients (86 males and 91 females, mean age: 66 y.o) suffering from Multiple Myeloma. Regarding MBD, 21%,19%,36% and 24% of the patients were bone scaled as 0,1,2 and 3 according to Durie-Salmon Bone Scale (D-SBS). Serum cytokines were measured by ELISA. Seventeen patients followed and treated in our section, with a total of 43 vertebral fractures were treated with kyphoplasty.Results: We found that those patients suffering from spontaneous fractures at diagnosis, representing the 24%, faced a worse outcome with median overall survival of 30 months compared to 86 months (p < 0.00001). Moreover, in MM patients certain cytokines were statistical correlated with parameters of skeletal manifestations. Dkk-1 was correlated in a positive manner with bone fractures (p=0.001). In addition, s-Syndecan-1 (p=0.024), b-FGF(p=0.016),TGF-b1(p=0.014) and VEGF (p=0,025) were correlated statistically significant with level of skeletal disease as scaled according to D-SBS. No statistical difference was noticed between serum RANKL levels, IL-6/IL-6R, IGF-1 and MBD. Myeloma Bone Disease can be treated with myeloma-directed chemotherapy and agents inhibiting bone resorption such as aminobisphosphonates (ABP), although new promising biology driven monoclonal antibodies targeting osteoclastogenesis mechanisms are emerging. Radiotherapy and Surgical approaches may control skeletal mechanical failure and relief from bone pain. We studied a cohort of MM patients (10women and 2 men) in a plateau phase, with bone disease manifestations (either lytic lesions or bone pain) that received ABP. Median s-synd-1 levels were 127ng/ml in all patients at treatment initiation. In 7 patients, they decreased six months after zolendronic acid administration and in these the initial median levels were 134 ng/ml and decreased to 57 ng/ml. One of these patients, a 79 years old women, with extensive osteolytic lesions of the skull presented remineralization after 6 months. In the other 5 patients, serum s-synd-1 levels remained stable in 3 and increased in 2 patients. Seventeen patients underwent kyphoplasty due to Vertebral Compression Fracture (VCF) secondary to MBD. All the patients tolerated the procedure well; they were discharged ambulatory the following morning of the procedure. In 23% of the VCFs, the deformity correction achieved 90% of the vertebral body height restoration, in 61% resulted to 60% - 89% restoration and for rest, the reduction was measured as 30% - 59%. For a median follow up time of 18 months (range 4 - 30) there were no early or late complications related to the technique as cement extravasations, relapse of the MM in the same VB or even refracture. All patients experienced immediate and stable pain relief (median VAS pro-post: 6 - 1) and improvement in the quality of life. Conclusion: Extended studies have concerned the regulation of RANK/ RANKL/OPG axis as a well-known contributor to bone microenvironment. Our study has presented results based on which s-Syndecan-1, TGF-β1 and angiocytokines possible also contribute to aspects of Myeloma Bone Disease. Myeloma is a morbid complication and should be carefully managed because it deteriorates patient’s quality of life and worsens disease outcome.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2014
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Stavropoulos, Nikolaos
- Σταυρόπουλος, Νικόλαος
Subjects
dc:subject × 14Rights
dc:rights- Statement dc:rights
-
- BY_NC_SA
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/39853